Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Using Telemetry Data to Refine Endpoints for New Zealand White Rabbits Challenged with Bacillus anthracis.

Dawson DG, Bower KA, Burnette CN, Holt RK, Swearengen JR, Dabisch PA, Scorpio A.

J Am Assoc Lab Anim Sci. 2017 Nov 1;56(6):792-801.

2.

Probing the donor and acceptor substrate specificity of the γ-glutamyl transpeptidase.

Hu X, Legler PM, Khavrutskii I, Scorpio A, Compton JR, Robertson KL, Friedlander AM, Wallqvist A.

Biochemistry. 2012 Feb 14;51(6):1199-212. doi: 10.1021/bi200987b. Epub 2012 Feb 2.

PMID:
22257032
3.

The cluster 1 type VI secretion system is a major virulence determinant in Burkholderia pseudomallei.

Burtnick MN, Brett PJ, Harding SV, Ngugi SA, Ribot WJ, Chantratita N, Scorpio A, Milne TS, Dean RE, Fritz DL, Peacock SJ, Prior JL, Atkins TP, Deshazer D.

Infect Immun. 2011 Apr;79(4):1512-25. doi: 10.1128/IAI.01218-10. Epub 2011 Feb 7.

4.

Capsule depolymerase overexpression reduces Bacillus anthracis virulence.

Scorpio A, Chabot DJ, Day WA, Hoover TA, Friedlander AM.

Microbiology. 2010 May;156(Pt 5):1459-67. doi: 10.1099/mic.0.035857-0. Epub 2010 Jan 28.

PMID:
20110296
5.

Treatment of experimental anthrax with recombinant capsule depolymerase.

Scorpio A, Tobery SA, Ribot WJ, Friedlander AM.

Antimicrob Agents Chemother. 2008 Mar;52(3):1014-20. Epub 2007 Dec 26.

6.

Poly-gamma-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis.

Scorpio A, Chabot DJ, Day WA, O'brien DK, Vietri NJ, Itoh Y, Mohamadzadeh M, Friedlander AM.

Antimicrob Agents Chemother. 2007 Jan;51(1):215-22. Epub 2006 Oct 30.

7.

Anthrax vaccines: Pasteur to the present.

Scorpio A, Blank TE, Day WA, Chabot DJ.

Cell Mol Life Sci. 2006 Oct;63(19-20):2237-48.

PMID:
16964578
8.

Anthrax capsule vaccine protects against experimental infection.

Chabot DJ, Scorpio A, Tobery SA, Little SF, Norris SL, Friedlander AM.

Vaccine. 2004 Nov 15;23(1):43-7.

PMID:
15519706
9.

The NheA component of the non-hemolytic enterotoxin of Bacillus cereus is produced by Bacillus anthracis but is not required for virulence.

Mendelson I, Tobery S, Scorpio A, Bozue J, Shafferman A, Friedlander AM.

Microb Pathog. 2004 Sep;37(3):149-54.

PMID:
15351038
10.

Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid.

Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z.

J Antimicrob Chemother. 2003 Nov;52(5):790-5. Epub 2003 Oct 16.

PMID:
14563891
11.
13.

Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.

Scorpio A, Lindholm-Levy P, Heifets L, Gilman R, Siddiqi S, Cynamon M, Zhang Y.

Antimicrob Agents Chemother. 1997 Mar;41(3):540-3.

14.

Rapid differentiation of bovine and human tubercle bacilli based on a characteristic mutation in the bovine pyrazinamidase gene.

Scorpio A, Collins D, Whipple D, Cave D, Bates J, Zhang Y.

J Clin Microbiol. 1997 Jan;35(1):106-10.

16.

Isolation of Borrelia burgdorferi from saliva of the tick vector, Ixodes scapularis.

Ewing C, Scorpio A, Nelson DR, Mather TN.

J Clin Microbiol. 1994 Mar;32(3):755-8.

Supplemental Content

Loading ...
Support Center